drugset / Trial / NCT02261883

Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn

NCT02261883

Phase 2 Terminated 42 enrolled United Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study assessed the safety and treatment effect of intravenous (IV) Remodulin as an add-on therapy in neonates with persistent pulmonary hypertension of the newborn (PPHN).

Timeline

Start
2015-07-29
Primary completion
2022-09-27
Completion
2023-05-17

Drugs

EvaluationDrugModalityDoseRoute
Comparator Treprostinil Other / unclassified 1 unknown Intravenous